<DOC>
	<DOCNO>NCT01152710</DOCNO>
	<brief_summary>A Phase II study aim evaluate efficacy toxicity preoperative chemoradiotherapy capecitabine locally advance resectable rectal cancer .</brief_summary>
	<brief_title>Capecitabine Radiosensitising Agent Neoadjuvant Treatment Locally Advanced Resectable Rectal Cancer</brief_title>
	<detailed_description>Preoperative chemoradiation become standard part treatment protocols stage II III rectal cancer . Compared postoperative chemoradiotherapy , advantage preoperative application chemotherapeutics irradiation include improved compliance , reduce toxicity downstaging tumour substantial number patient . The latter may enhance rate curative surgery , permit sphincter preservation patient low-sited tumour positive impact quality life patient . Orally administer capecitabine ( XelodaÂ® , Hoffmann - La Roche Ltd , Basel , Switzerland ) mimic pharmacokinetics continuous 5-FU infusion make chemoradiotherapy patient-friendly . The mechanism capecitabine activation , preferably tumour cell , may enhance efficacy tolerability , offer potential enhance therapeutic ratio.The aim present phase II study evaluate efficacy toxicity preoperative chemoradiotherapy capecitabine patient locally advanced rectal cancer . The primary endpoint study pathologically determine complete remission rate ( pCR ) disease locally regionally . Secondly , rate sphincter preservation low-sited tumour , overall downstaging rate , toxicity survival parameter analyse .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>histologically verify adenocarcinoma rectum , resectable clinical stage II III ( IUCC TNM classification 2002 ) ; prior radiotherapy and/or chemotherapy ; World Health Organisation ( WHO ) performance status &lt; 2 ; age diagnosis 18 old ; adequate bone marrow , liver , renal cardiac function ( history ischemic heart disease ) . A history prior malignancy nonmelanoma skin cancer situ carcinoma cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>capecitabine</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>phase II study</keyword>
</DOC>